HK:2162 Stock Latest News
PremiumCompany AnnouncementsKeymed Biosciences Licenses CM355 to Prolium for Global Development Keymed Biosciences Secures Licensing Deal for CM313 Keymed Biosciences Gains NMPA Approval for Stapokibart PremiumCompany AnnouncementsKeymed Biosciences Faces Steep Revenue Decline Keymed Biosciences Schedules Crucial Financial Meeting Keymed Biosciences Strikes Global Licensing Deal PremiumCompany AnnouncementsKeymed Reports Promising Cancer Drug Results Keymed Biosciences’ Stapokibart Gains Priority Review